Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.38 |
| ▸ | PGR | P06401 | 6/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 5/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629332 | 0.85 | NR3C1 (0.38) | NR3C1PGRNR3C2ARLCK | |
| SCHEMBL1629078 | 0.83 | MEN1 (0.37) | NR3C1PGRNR3C2MAP4K1AR | |
| SCHEMBL1629246 | 0.81 | PGR (0.63) | NR3C1PGRNR3C2MAP4K1AR | |
| SCHEMBL1630970 | 0.74 | NR3C1 (0.44) | NR3C1PGRNR3C2ARLCK | |
| SCHEMBL1631816 | 0.74 | PGR (0.63) | NR3C1PGRNR3C2ARLCK | |
| SCHEMBL28592975 | 0.70 | XDH (0.45) | NR3C1PGRNR3C2ARKDM4E | |
| SCHEMBL1629514 | 0.70 | NR3C1 (0.39) | NR3C1PGRNR3C2AR | |
| SCHEMBL1629405 | 0.69 | NR3C1 (0.39) | NR3C1PGRNR3C2ARKDM1A | |
| SCHEMBL1631975 | 0.68 | PGR (0.66) | NR3C1PGRNR3C2ARKDR | |
| SCHEMBL1629330 | 0.67 | PGR (0.64) | NR3C1PGRNR3C2ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979314-B1 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| CN-101374808-B | Indole sulfonamide modulators of progesterone receptors | LILLY CO ELI | 2011-05-25 | — | — | CN | disclosed |
| US-7932284-B2 | Indole sulfonamide modulators of progesterone receptors | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| CN-101374808-A | Indole sulfonamide modulators of progesterone receptors | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | disclosed |
| EP-1979314-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | Eli Lilly & Company (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087488-A9 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007087488-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | NR3C1 63/4885PGR 1/4885NR3C2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.